This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Cerebral cavernous malformation 2 (CCM2); serine/threonine kinase 25 (STK25)	<i>In vitro</i> studies suggest increasing STK25 activity could help treat pediatric neural cancers. In human embryonic fibroblasts, STK25-targeting small hairpin RNA decreased CCM2-dependent cell death compared with control shRNA. In 478 patients with neuroblastoma, high STK25 levels were correlated with increased overall survival. Next steps include identifying small molecules that affect the expression or interactions of STK25 and CCM2. <i>SciBX</i> 5(30); doi:10.1038/scibx.2012.782 Published online Aug. 2, 2012	Unpatented; licensing status not applicable	Costa, B. <i>et al. J. Biol. Chem.</i> ; published online July 10, 2012; doi:10.1074/jbc.C112.345397 Contact: Mike Fainzilber, Weizmann Institute of Science, Rehovot, Israel e-mail: mike.fainzilber@weizmann.ac.il Contact: Barbara Costa, same affiliation as above e-mail: barbara.costa@weizmann.ac.il